Effective regimens for the treatment of<i>Helicobacter pylori</i>infection

Morgner, Andrea; Labenz, Joachim; Miehlke, Stephan

doi:10.1517/13543784.15.9.995

Cited by 21 publications

(16 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3]95 Here, quadruple therapy is recommended, although the second eradication may also fail in up to 30-40% of the cases as was shown by expert opinion, 96 a systematic review 97 and our own experience. 78 F-based second-line therapies obtained eradication rates as high as the primary regimens, suggesting that this compound could be usefully included in the second-line combinations.…”

Section: Discussionmentioning

confidence: 91%

“…Administering the most effective recommended regimens, proton pump inhibitors (PPI) + two antimicrobials, approximately 20% of the compliant patients will fail to overcome the infection. [1][2][3] Factors influencing the success or failure of a regimen are the patient's compliance and antimicrobial resistance; therefore, the appropriate selection of the patients and choice of antibiotics is of pivotal importance to the treatment outcome. 4,5 According to the European, US, Asian-Pacific and Latin-American Consensus, the standard therapy comprises any of the available PPI + clarithromycin (C) and either amoxicillin (A) or metronidazole (M), all administered b.i.d.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Buzás¹,

Józan

2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

Several aspects of Helicobacter pylori eradication have been meta-analyzed; however, nitrofuran-based therapies constitute an exception. The aim of this study was the systematic review and meta-analysis of the effect of furazolidone-and nitrofurantoin-based regimens in the eradication of infection. Studies evaluating the effects of nitrofurans on H. pylori were identified from Medline, EMBASE, the Cochrane Controlled Trials Register and congress abstracts. The studies were classified into groups based on first-, second-and third-line regimens. The pooled eradication rates and combined odd ratios of the individual studies were calculated and compared with the published meta-analysis. The factors influencing the efficiency of the regimens were also analyzed. Side-effects of nitrofuranbased regimens were also analyzed. The pooled eradication rate of primary proton pump inhibitor-based regimens containing furazolidone was 76.3% .2). The odds ratio for furazolidone-based regimens versus standard triple therapies was 2.34 (CI 0.76-3.92). Ranitidine bismuth citrate + furazolidone-based triple regimens were equally efficient (83.5%, CI 74.0-93.0, P = 0.06 versus triple therapies). Schedules including a H2 antagonist + furazolidone + one other antibiotic achieved pooled eradication rates of 79.9% (CI 67.8-89.9, P = 0.04). Bismuth-based triple therapies achieved 84.5% (CI 72.6-93.0, P = 0.002). Primary quadruple regimens containing furazolidone were superior to triple therapies (83.4%, CI 69.7-92.3, P = 0.01). Second-line schedules containing furazolidone obtained eradication rates of 76.1% (CI 66.4-85.0, P = 0.28 versus primary regimens). Third-line 'rescue' therapies were efficient in 65.5% of the cases (CI 56.3-75.5, P = 0.0001). Side-effects of the regimens containing furazolidone were more frequent than in standard therapies (P = 0.02). The combined odds ratio of side-effects for furazolidonebased versus standard therapies was 0.74 (CI 0.32-1.98). The duration of treatment, but not the furazolidone dose, influenced the treatment outcome. Primary triple regimens containing furazolidone are slightly less efficient than the standard primary combinations; primary quadruple regimens were more efficient than triple therapies. Furazolidone is also efficient as a component of second-line or rescue therapies.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Buzás¹,

Józan

2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…However, it remains in common use in veterinary medicine, especially on poultry, in the Middle and Far Eastern countries [4,11]. In these countries, FZ is also used on meatproducing and aquatic animals and to treat infectious diseases in humans, especially Helicobacter pylori infection [16,18].…”

mentioning

confidence: 99%

Antibiotic Furazolidone Induces CYP1A But Not CYP2E1 Subfamily in Rat Liver

Sasaki

Sakai

Ikenaka

et al. 2008

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Furazolidone (FZ), one of the nitrofuran fungicides, is used as a veterinary medicine in the Middle and Far Eastern countries. In this study, FZ (125 mg/kg) was administered orally to Wistar rats for 3 days. Results of the Ames test using the S-9 fraction of rats treated with FZ showed a significant increase in the number of revertant colonies. Western blot analysis of hepatic CYP isozymes induced by FZ, revealed a remarkable induction of CYP1A1 apoprotein, but CYP1A2 and CYP2E1 apoproteins were not altered. In addition, the expression of CYP1A1 mRNA level in rats treated with FZ by RT-PCR was significantly enhanced by FZ treatment. We concluded that FZ is apparently mutagenic and induces transcription of the CYP1A1 isozyme, which metabolically activates numerous promutagens, in hepatocytes.

show abstract

“…But due to the indolent nature of the lymphoma a careful watch-and-wait strategy seems to be justified [24,25] . To date, eradication therapy in H pyloripositive, primary gastric MALT lymphoma patients with localized stageⅠdisease has to be considered as treatment of choice with any of the highly effective antibiotic regimens proposed can be used [62,63] . The role of eradication therapy in stage Ⅱ lymphomas is still under discussion.…”

Section: What Stage-what Kind Of Therapy?mentioning

confidence: 99%

Therapy of gastric mucosa associated lymphoid tissue lymphoma

Morgner

Schmelz²,

Thiede³

et al. 2007

WJG

Self Cite

View full text Add to dashboard Cite

Gastric mucosa associated lymphoid tissue (MALT) lymphoma has recently been incorporated into the World Health Organization (WHO) lymphoma classification, termed as extranodal marginal zone B-cell lymphoma of MALT-type. In about 90% of cases this lymphoma is associated with H pylori infection which has been clearly shown to play a causative role in lymphomagenesis. Although much knowledge has been gained in defining the clinical features, natural history, pathology, and molecular genetics of the disease in the last decade, the optimal treatment approach for gastric MALT lymphomas, especially locally advanced cases, is still evolving. In this review we focus on data for the therapeutic, stage dependent management of gastric MALT lymphoma. Hence, the role of eradication therapy, surgery, chemotherapy and radiotherapy is critically analyzed. Based on these data, we suggest a therapeutic algorithm that might help to better stratify patients for optimal treatment success.

show abstract

Effective regimens for the treatment ofHelicobacter pyloriinfection

Cited by 21 publications

References 171 publications

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Antibiotic Furazolidone Induces CYP1A But Not CYP2E1 Subfamily in Rat Liver

Therapy of gastric mucosa associated lymphoid tissue lymphoma

Contact Info

Product

Resources

About